ロード中...
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metasta...
保存先:
| 出版年: | Int J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Japan
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809574/ https://ncbi.nlm.nih.gov/pubmed/28770408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-017-1176-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|